TL;DR
Brain fog is no longer a vague, dismissible complaint — it's a clinical signal increasingly linked to treatable root causes like perimenopause, hypothyroidism, and chronic inflammation. With millions of patients reporting cognitive decline post-COVID and during hormonal transitions, the condition's overlooked triggers are now driving a shift in how primary care physicians screen for underlying disease.
What Happened
Dr. Aneesa Das, a cognitive health specialist, published a column in The Washington Post on Monday, August 10, 2026, identifying five surprising causes of brain fog that routinely escape standard medical workups. The piece arrives as brain fog transitions from a colloquial catch-all into a formal diagnostic consideration, particularly for the estimated 6 million American women navigating perimenopause and the 27 million adults living with undiagnosed thyroid dysfunction.
Key Facts
- Perimenopause — often dismissed as "just stress" — is now recognized as a primary driver of cognitive slowing, with estrogen fluctuations affecting hippocampal activity and verbal memory retrieval in women aged 40–55.
- Hypothyroidism affects approximately 5–10% of the population, yet nearly 60% of those affected are unaware; the cognitive impact — slowed processing speed and working memory deficits — is frequently misattributed to aging or depression.
- Chronic low-grade inflammation from conditions like autoimmune disorders, insulin resistance, and even periodontal disease has been linked to impaired neural signaling, with C-reactive protein (CRP) levels above 3.0 mg/L correlating with measurable cognitive decline.
- Medication side effects — particularly from anticholinergic drugs, proton pump inhibitors, and certain statins — are implicated in up to 12% of brain fog cases in adults over 50.
- Sleep-disordered breathing, including mild obstructive sleep apnea (OSA) with an AHI score of just 5–15 events per hour, can reduce oxygen saturation and fragment deep sleep, producing brain fog that mimics early dementia.
- Vitamin B12 deficiency — affecting 6% of adults under 60 and 20% of those over 60 — presents with cognitive symptoms that are fully reversible with supplementation when caught early.
- The column follows the 2025 inclusion of brain fog as a recognized symptom cluster in the International Classification of Diseases (ICD-11) for post-COVID syndrome, legitimizing patient-reported cognitive complaints in clinical billing and research.
Breaking It Down
The Washington Post column lands at a pivotal moment in cognitive medicine. For decades, brain fog was treated as a psychological artifact — something to be managed with antidepressants or sleep hygiene rather than investigated as a physiological phenomenon. That framing is collapsing under the weight of post-COVID research, which has documented structural brain changes — including reduced gray matter in the insula and temporal lobes — in patients reporting persistent cognitive symptoms months after infection.
The most striking figure in the column's analysis: approximately 40% of brain fog cases traced to perimenopause and thyroid dysfunction resolve within 12 weeks of targeted treatment — meaning a substantial portion of cognitive decline in middle-aged adults is not degenerative, but reversible.
This statistic reframes the clinical urgency. If nearly half of brain fog presentations stem from treatable hormonal or metabolic imbalances, then the current standard of care — which often involves a referral to neurology for an MRI and a "wait and see" approach — is both expensive and dangerously slow. The column argues for a first-line screening panel including TSH, free T4, vitamin B12, CRP, and a comprehensive medication review before advanced neuroimaging is considered.
The perimenopause angle is particularly significant given the demographic shift. With 4,000 women in the U.S. transitioning through menopause each day, and the average age of onset at 51, the cognitive symptoms of this transition — often described as "brain fog" by patients — are now being recognized as a legitimate endocrine phenomenon rather than a psychological failing. The column notes that estrogen replacement therapy, when initiated within the "window of opportunity" (typically within 10 years of menopause onset), shows measurable improvement in verbal memory and processing speed in 65–70% of treated women.
The medication angle is perhaps the most actionable. The column highlights that anticholinergic burden — the cumulative effect of drugs that block acetylcholine — is a modifiable risk factor. Common culprits include diphenhydramine (Benadryl), oxybutynin (Ditropan), and certain tricyclic antidepressants. Deprescribing protocols, where physicians systematically reduce or replace these medications, have demonstrated cognitive improvement in 80% of affected patients within 6–8 weeks.
What Comes Next
The column's publication is likely to catalyze several concrete developments in the coming months:
-
The American Thyroid Association's annual meeting (September 2026) — Expect new clinical guidance on cognitive screening for hypothyroid patients, potentially recommending cognitive assessments as standard for newly diagnosed adults over 40.
-
FDA advisory committee review (October 2026) — A scheduled panel on menopausal treatments will likely evaluate data on cognitive outcomes, potentially expanding approved indications for low-dose estrogen therapy to explicitly include brain fog.
-
The National Institutes of Health's RECOVER Initiative — The ongoing post-COVID study, with a $1.15 billion budget, is slated to release its final cognitive outcomes report in Q1 2027, which may formalize brain fog treatment protocols for the estimated 16 million Americans with long COVID.
-
Medicare coverage expansion (January 2027) — The Centers for Medicare & Medicaid Services is reviewing whether to add comprehensive thyroid panels and B12 testing to annual wellness visits, a move that would make screening routine for 67 million beneficiaries.
The Bigger Picture
This story sits at the intersection of two major health trends: the hormonal health revival and the functional medicine shift. The former — driven by a new generation of clinicians and telehealth platforms like Midi Health and Evernow — has normalized conversations about perimenopause and menopause that were taboo a decade ago. The latter reflects a broader move away from symptom suppression toward root-cause investigation, with direct-to-consumer lab testing and wearable sleep trackers empowering patients to bring data to their doctor visits.
The column also reinforces the post-COVID cognitive awareness movement. Before 2020, brain fog was rarely discussed in mainstream medical literature. Today, it anchors entire research programs and patient advocacy efforts. The convergence of these trends means brain fog is no longer a complaint to be dismissed — it's a diagnostic opportunity that could transform how we screen for endocrine, inflammatory, and metabolic disease in primary care.
Key Takeaways
- Reversibility is high: Up to 40% of brain fog cases stem from treatable conditions like perimenopause and thyroid dysfunction, with symptoms often resolving within 12 weeks of targeted treatment.
- Screening matters more than imaging: A basic panel of TSH, vitamin B12, CRP, and a medication review can catch more actionable causes than an MRI in most middle-aged patients.
- Medications are a hidden culprit: Anticholinergic drugs and other common prescriptions contribute to up to 12% of brain fog cases — and deprescribing helps 80% of affected patients.
- The conversation has shifted: With brain fog now in the ICD-11 and central to post-COVID research, patients have more legitimacy — and more leverage — in demanding thorough workups.
